CN115068500A - 一种治疗幽门螺杆菌的药物 - Google Patents
一种治疗幽门螺杆菌的药物 Download PDFInfo
- Publication number
- CN115068500A CN115068500A CN202210695350.9A CN202210695350A CN115068500A CN 115068500 A CN115068500 A CN 115068500A CN 202210695350 A CN202210695350 A CN 202210695350A CN 115068500 A CN115068500 A CN 115068500A
- Authority
- CN
- China
- Prior art keywords
- helicobacter pylori
- chlorite
- parts
- treatment
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 25
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 title claims description 9
- 229910001919 chlorite Inorganic materials 0.000 claims abstract description 12
- 229910052619 chlorite group Inorganic materials 0.000 claims abstract description 12
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 239000003381 stabilizer Substances 0.000 claims abstract description 9
- 239000000945 filler Substances 0.000 claims abstract description 5
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical group OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical group [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 229940085605 saccharin sodium Drugs 0.000 claims description 6
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical group [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 claims description 6
- 229960002218 sodium chlorite Drugs 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- QXIKMJLSPJFYOI-UHFFFAOYSA-L calcium;dichlorite Chemical compound [Ca+2].[O-]Cl=O.[O-]Cl=O QXIKMJLSPJFYOI-UHFFFAOYSA-L 0.000 claims description 3
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical compound [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 abstract description 7
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 24
- 239000004155 Chlorine dioxide Substances 0.000 description 12
- 235000019398 chlorine dioxide Nutrition 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0068—Rumen, e.g. rumen bolus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗幽门螺杆菌的药物；包括以下质量计组分：包括以下质量计组分：亚氯酸盐30份、稳定剂3份、口感剂1份和填充剂66份，可制成滴剂或药片。本发明代替传统的三联疗法和四联疗法，灭幽门螺旋杆菌效果好，不产生抗药性，并能够对消化道进行养护，且服用过程方便快捷，易于接受。
Description
技术领域
本发明属于药物领域，具体涉及一种治疗幽门螺杆菌的药物。
背景技术
幽门螺旋杆菌是众多消化道疾病的元凶，是一种比较难杀灭的细菌，能够对组装膜造成损坏，从而造成一系列消化道疾病。
幽门螺杆菌分三联疗法和四联疗法,四联疗法是指一种质子泵抑制剂或一种铋剂,再加两种抗生素,质子泵抑制剂包括奥美拉唑、兰索拉唑、泮托拉唑、雷贝拉唑、艾索美拉唑等药物。
专利CN201510114050.7、CN104666330A、CN201510111272.3中提到使用纯二氧化氯溶液杀灭幽门螺杆菌，但是有强烈的刺激性气味，患者难以服用。且二氧化氯溶液很难保存，有效期通常只有15天，很难商品化，服用过程较为麻烦，且采用的抗生素容易产生细菌抗药性，造成反复感染。
发明内容
本发明的目的在于提供一种治疗幽门螺杆菌的药物，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：一种治疗幽门螺杆菌的药物，包括以下质量计组分：亚氯酸盐30份、稳定剂3份、口感剂1份和填充剂66份，制成滴剂或药片。
较佳的，所述亚氯酸盐为亚氯酸钠、亚氯酸钾、亚氯酸钙。
较佳的，所述稳定剂为碳酸氢钠、氢氧化钠、磷酸氢二钠。
较佳的，所述口感剂为糖精钠、阿巴斯甜、三氯蔗糖。
较佳的，所述填充剂为麦芽糊精、淀粉、碳酸钙。
较佳的，所述滴剂的制备工艺包括：将亚氯酸盐、稳定剂、口感剂先用分散电机充分分散均匀，之后采用明胶与辅助材料制造而成的卵状空心外壳制造出胶囊壳，采用胶囊灌装机将混合后的物料密封注入至胶囊壳内，形成滴剂。
较佳的，所述药片的制备工艺包括：将亚氯酸盐、稳定剂、口感剂先用分散电机充分分散均匀，之后加入淀粉和明胶，利用压片机压制成片，形成药片。
与现有技术相比，本发明的有益效果是：
本发明采用了以亚氯酸钠或亚氯酸盐为主要成分的药物，代替传统的三联疗法和四联疗法，灭菌效果好，不产生抗药性，并能够对消化道进行养护，且服用过程方便快捷，易于接受。胃的容积为1-1.5L，本发明的目的是在胃部形成1－5ppm浓度的二氧化氯，二氧化氯在酸性环境中起到很好的杀菌效果，二氧化氯会和胃部和肠道前端的有机物反应，30分钟后逐渐失去效果，但进入肠道后，为中性环境又会失去杀菌效果，从而保护肠道有益菌。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
本发明提供一种技术方案：一种治疗幽门螺杆菌的药物，包括以下质量计组分：
亚氯酸钠30份、碳酸氢钠3份、糖精钠1份和麦芽糊精66份，使用压片机压成0.2g的药片。
实施例2
本发明提供一种技术方案：一种治疗幽门螺杆菌的药物，包括以下质量计组分：
亚氯酸钾30份、碳酸氢钠3份、糖精钠1份和麦芽糊精66份，使用压片机压成0.2g的药片。
实施例3
本发明提供一种技术方案：一种治疗幽门螺杆菌的药物，包括以下质量计组分：
亚氯酸钙30份、碳酸氢钠3份、糖精钠1份和碳酸钙66份，使用压片机压成0.2g的药片。
实施例4
本发明提供一种技术方案：一种治疗幽门螺杆菌的药物，包括以下质量计组分：
亚氯酸钠30份、碳酸氢钠3份、糖精钠1份和水66份，全部溶解制成滴剂。
本发明创新性使用亚氯酸盐治疗幽门螺杆菌，患者服用亚氯酸盐后，和胃酸反应，胃酸的主要成分是盐酸，亚氯酸钠和盐酸反应生成二氧化氯，从而杀灭胃部的幽门螺杆菌。反应方程式如下：
5NaClO2+4HCl═4ClO2+5NaCl+2H2O
胃的容积为1-1.5L，本发明的目的是在胃部形成1－5ppm浓度的二氧化氯，二氧化氯在酸性环境中起到很好的杀菌效果，二氧化氯会和胃部和肠道前端的有机物反应，30分钟后逐渐失去效果，但进入肠道后，为中性环境又会失去杀菌效果，从而保护肠道有益菌。
实验：
幽门螺杆菌简称Hp，10名HP志愿患者口服实施例1/2/3/4和安慰剂组，测试效果：
| 实施例1 | 实施例2 | 实施例3 | 实施例4 | 安慰剂 | |
| 第1天 | 口气减轻 | 口气减轻 | 口气减轻 | 口气减轻 | 有口气 |
| 第2天 | 口气消失 | 口气消失 | 口气消失 | 口气消失 | 有口气 |
| 第7天 | 转阴 | 转阴 | 转阴 | 转阴 | 无明显变化 |
第一天，口服实施例1药片早晚各一次1片，口气减轻；
第二天，口服实施例1药片早晚各一次1片，口气消失，反酸症状消失；
口服7天后，经碳14呼气试验测定幽门螺杆菌为阴性。
尽管已经示出和描述了本发明的实施例，对于本领域的普通技术人员而言，可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型，本发明的范围由所附权利要求及其等同物限定。
Claims (7)
1.一种治疗幽门螺杆菌的药物，其特征在于：包括以下质量计组分：亚氯酸盐30份、稳定剂3份、口感剂1份和填充剂66份，制成滴剂或药片。
2.根据权利要求1所述的一种治疗幽门螺杆菌的药物，其特征在于：所述亚氯酸盐为亚氯酸钠、亚氯酸钾、亚氯酸钙。
3.根据权利要求1所述的一种治疗幽门螺杆菌的药物，其特征在于：所述稳定剂为碳酸氢钠、氢氧化钠、磷酸氢二钠。
4.根据权利要求1所述的一种治疗幽门螺杆菌的药物，其特征在于：所述口感剂为糖精钠、阿巴斯甜、三氯蔗糖。
5.根据权利要求1所述的一种治疗幽门螺杆菌的药物，其特征在于：所述填充剂为麦芽糊精、淀粉、碳酸钙。
6.根据权利要求1所述的一种治疗幽门螺杆菌的药物，其特征在于：所述滴剂的制备工艺包括：将亚氯酸盐、稳定剂、口感剂先用分散电机充分分散均匀，之后采用明胶与辅助材料制造而成的卵状空心外壳制造出胶囊壳，采用胶囊灌装机将混合后的物料密封注入至胶囊壳内，形成滴剂。
7.根据权利要求1所述的一种治疗幽门螺杆菌的药物，其特征在于：所述药片的制备工艺包括：将亚氯酸盐、稳定剂、口感剂先用分散电机充分分散均匀，之后加入淀粉和明胶，利用压片机压制成片，形成药片。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210695350.9A CN115068500A (zh) | 2022-06-20 | 2022-06-20 | 一种治疗幽门螺杆菌的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210695350.9A CN115068500A (zh) | 2022-06-20 | 2022-06-20 | 一种治疗幽门螺杆菌的药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115068500A true CN115068500A (zh) | 2022-09-20 |
Family
ID=83254137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210695350.9A Pending CN115068500A (zh) | 2022-06-20 | 2022-06-20 | 一种治疗幽门螺杆菌的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115068500A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989003179A1 (en) * | 1987-10-13 | 1989-04-20 | New Generation Products, Inc. | Chlorine dioxide germicidal composition |
| CN104666330B (zh) * | 2015-03-17 | 2018-03-16 | 深圳市仝森林科技有限公司 | 纯二氧化氯溶液制备内用消毒剂的应用 |
| CN110996941A (zh) * | 2017-05-04 | 2020-04-10 | 沃尔特·绍布 | 用于治疗病原体感染的组合物和治疗过程 |
-
2022
- 2022-06-20 CN CN202210695350.9A patent/CN115068500A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989003179A1 (en) * | 1987-10-13 | 1989-04-20 | New Generation Products, Inc. | Chlorine dioxide germicidal composition |
| CN104666330B (zh) * | 2015-03-17 | 2018-03-16 | 深圳市仝森林科技有限公司 | 纯二氧化氯溶液制备内用消毒剂的应用 |
| CN110996941A (zh) * | 2017-05-04 | 2020-04-10 | 沃尔特·绍布 | 用于治疗病原体感染的组合物和治疗过程 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU707749B2 (en) | Medical Treatment | |
| US3337404A (en) | Effervescent potassium composition | |
| CN108464963A (zh) | 一种用于口腔的组合物及其应用和制备方法 | |
| US20150272873A1 (en) | Effervescent tablet | |
| CN115068500A (zh) | 一种治疗幽门螺杆菌的药物 | |
| CN102772383A (zh) | 阿奇霉素组合物冻干口腔崩解片及其制备方法 | |
| CN105832993B (zh) | 一种具有清咽功能的组合物及其制备方法和应用 | |
| CN108125940B (zh) | 戊酸在制备用于预防和/或治疗肿瘤放疗副反应的药物中的用途 | |
| KR20070091041A (ko) | 포비돈요오드를 함유하는 구강내 붕괴형의 고형 제제 | |
| CN110327423A (zh) | 一种含有白芨提取物成分的口腔科和喉科的消炎用喷剂 | |
| CN104324062A (zh) | 西洋参转化皂苷、其中药口腔护理组合物及制备方法和应用 | |
| JP6315741B2 (ja) | ＮＳＡＩＤｓまたはヘパリン類含有口腔用組成物 | |
| CN105726491A (zh) | 治疗肠胃疾病的聚六亚甲基胍药物及其制备方法和应用 | |
| CN107308213A (zh) | 一种无花果泡腾片及其生产方法 | |
| WO2000074685A1 (fr) | Preparations orales d'etidronate disodique | |
| CN106420811A (zh) | 一种氨基糖苷类抗生素的口服制剂及其制备方法与应用 | |
| CN105709140A (zh) | 一种治疗过敏性肺炎的药物组合物及其制备方法 | |
| CN111000871A (zh) | 一种口腔喷剂及其制备方法 | |
| CN102784121A (zh) | 左氧氟沙星组合物冻干口腔崩解片及其制备方法 | |
| US12053447B2 (en) | Oral solution and powder to liquid compositions of balsalazide | |
| CN106474149A (zh) | 一种复方氨基糖苷类抗生素的口服制剂及其制备方法与应用 | |
| WO2018113042A1 (zh) | 一种药物制剂在制备治疗幽门螺杆菌感染性疾病的药物中的应用 | |
| CN107320445B (zh) | 一种盐酸氨溴索注射液及其制备方法 | |
| CN101919799B (zh) | 缓释透皮给药系统 | |
| RU2398589C1 (ru) | Средство "экспортал", обладающее гастропротективным (противоязвенным) действием |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220920 |
|
| RJ01 | Rejection of invention patent application after publication |